Office Action dated August 8, 2005

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 (original): N-phenyl-2-pyrimidine-amine derivative represented by the following formula (1):

$$R_3$$
 N
 R_4
 R_5
 R_6
 R_7
 R_8
 R_8
 R_8
 R_8
 R_9
 R_9

and its salt, in which

R₁ represents 3-pyridyl or 4-pyridyl,

R₂ and R₃ each represent hydrogen or lower alkyl,

 R_6 or R_7 represents a radical having the following formula (2):

$$-N = C_{H_2}(X) - R_s$$
 (2)

wherein X represents oxygen or NH, n=0 or 1, and R₉ represents aliphatic having 5 to 10 carbon atoms, or represents 5 to 7 membered saturated or unsaturated monocyclic radical, or bi- or tri-cyclic radical optionally combined with benzene ring, each of which has 1 to 3 hetero atoms selected from a group consisting of nitrogen, oxygen and sulfur, or represents piperazinyl or homopiperazinyl each of which is substituted by lower alkyl, and

 R_4 , R_5 , R_7 , and R_8 each represent hydrogen, or one or two thereof each represent halogen, lower alkyl, or lower alkoxy when R_6 represents the radical of the above formula (2), or one or two of R_4 , R_5 , R_6 , and R_8 each represent halogen, lower alkyl,

Application No.: 10/806,834 Amendment dated November 7, 2005

Office Action dated August 8, 2005

or lower alkoxy when R_7 represents the radical of the above formula (2), provided that R_6 or R_7 represents a radical of formula (2) wherein n=0 and R_9 is 4-methylpiperazine, then one or more of R_4 , R_5 , R_7 , and R_8 , or one or more of R_4 , R_5 , R_6 , and R_8 are halogen.

2 (original): The compound of claim 1 wherein

R₁ represents 3-pyridyl,

R₂ and R₃ each represent hydrogen,

R₆ or R₇ represents a radical having the following formula (2):

$$-\underline{N} \xrightarrow{O} -\underline{C}_{H_2}(X)_{n} - R_{s}$$
(2)

wherein X represents NH, n=0 or 1, and R_9 represents piperidine, 4-methylhomopiperazine, or 4-methylpiperazine, and

 R_4 , R_5 , R_7 , and R_8 each represent hydrogen, or one or two thereof each represent fluoro, methyl, or methoxy when R_6 represents the radical of the above formula (2), or one or two of R_4 , R_5 , R_6 , and R_8 each represent fluoro, methyl, or methoxy when R_7 represents the radical of the above formula (2).

3 (original): The compound of claim 1 wherein R_1 represents 3-pyridyl, R_2 , R_3 , R_4 , R_5 , R_7 , and R_8 each represent hydrogen, and R_6 represents the radical of formula (2) wherein n=0 and R_9 represents 4-methylhomopiperazine, or n=1, X represents NH, and R_9 represents 4-methylpiperazine.

4 (original): The compound of claim 1 wherein R_1 represents 3-pyridyl, R_2 and R_3 each represent hydrogen, R_4 represents methyl, R_5 , R_6 and R_8 each represent hydrogen, and R_7 represents the radical of formula (2) wherein n=1, X represents NH, and R_9 represents 4-methylpiperazine.

5 (cancelled).

Application No.: 10/806,834 -4- Docket No.: 59300CIP(71970)

Amendment dated November 7, 2005 Office Action dated August 8, 2005

6 (original): A pharmaceutical composition for the treatment of lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer, or cervical cancer, which comprises an effective amount of the compound of formula (1) or its salt as defined in claim 1 as an active ingredient together with pharmaceutically acceptable inert carriers.

7 (original): The composition of claim 6 which is used as an oral preparation.

8 (original): The composition of claim 6 which is used as an injection.

9 (cancelled).